ACRS — Aclaris Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $84.90m
- -$26.19m
- $31.25m
- 28
- 43
- 29
- 25
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 4.23 | 6.48 | 6.76 | 29.8 | 31.2 |
Cost of Revenue | |||||
Gross Profit | 0.172 | 1.35 | 2.05 | 17.8 | 13.2 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 115 | 57.4 | 96.5 | 120 | 129 |
Operating Profit | -111 | -50.9 | -89.7 | -89.9 | -97.4 |
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -114 | -51.3 | -90.9 | -86.9 | -88.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -114 | -51.2 | -90.9 | -86.9 | -88.5 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -161 | -51 | -90.9 | -86.9 | -88.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -161 | -51 | -90.9 | -86.9 | -88.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.3 | -1.2 | -1.6 | -1.33 | -1.19 |